Ascendis Pharma A/S (NASDAQ:ASND) Shares Bought by Diversified Trust Co

Diversified Trust Co increased its position in Ascendis Pharma A/S (NASDAQ:ASND) by 7.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,038 shares of the biotechnology company’s stock after buying an additional 3,114 shares during the period. Diversified Trust Co owned about 0.07% of Ascendis Pharma A/S worth $6,200,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth $60,000. Janus Henderson Group PLC lifted its position in Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after buying an additional 267,881 shares during the period. Avoro Capital Advisors LLC grew its holdings in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after buying an additional 229,995 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after acquiring an additional 155,971 shares during the period.

Ascendis Pharma A/S Stock Up 0.6 %

Shares of Ascendis Pharma A/S stock traded up $0.87 on Tuesday, hitting $141.15. 98,675 shares of the company’s stock traded hands, compared to its average volume of 301,483. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00. The stock has a market cap of $8.57 billion, a P/E ratio of -17.47 and a beta of 0.65. The firm’s 50-day moving average is $131.85 and its 200 day moving average is $133.52.

Analyst Upgrades and Downgrades

ASND has been the subject of several research analyst reports. UBS Group began coverage on shares of Ascendis Pharma A/S in a research report on Tuesday. They set a “buy” rating and a $196.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Stifel Nicolaus lifted their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. Citigroup upped their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Finally, Evercore ISI boosted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average target price of $192.07.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.